Abiopharma

🔍 Garner Ebun (Executive)

Company: Erasca, Inc. (ERAS)

Report Date: 2025-12-15

Detailed Transactions and Holdings:

• Acquired 3,902 shares of Common Stock at $1.1943 per share (Direct)
  Date: 2025-12-15 | Code: A | equity_swap_involved: false | shares_owned_after: 25,076.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 120,000 shares of Common Stock at $1.7 per share (Direct)
  Date: 2026-01-07 | Code: M | equity_swap_involved: false | shares_owned_after: 145,076.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 120,000 shares of Common Stock at $5.5901 per share (Direct)
  Date: 2026-01-07 | Code: S | equity_swap_involved: false | shares_owned_after: 25,076.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 120,000 shares of Stock Option (right to buy) at $1.7 per share (Derivative)
  Date: 2025-01-07 | Code: M | Expires: 2034-02-04 | equity_swap_involved: false | shares_owned_after: 360,000.00 | transaction_form_type: 4 | Footnotes: F2, F4

Footnotes:

• F1: The purchase price was calculated in accordance with the Issuer's 2021 Employee Stock Purchase Plan.
• F2: The exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 30, 2024.
• F3: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.50 to $5.80. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F4: The shares subject to this option award are fully vested and exercisable as of the date hereof.